BRD4 and ovarian carcinoma: Pre-clinical studies demonstrated that the pharmaceutical inhibition of BRD4 or BRD4 knockdown contribute to homologous recombination defects (HRD), sensitizing ovarian carcinoma cells to Poly (ADP-ribose) polymerase inhibitors (PARPi), regardless of their BRCA mutation status [117, 118].